EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Risks of Dementia Associated With Anticholinergic Medication Compared to Beta‐3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study

Yuki Okita, Yoshimitsu Shimomura, Sho Komukai, Ling Zha, Masayo Komatsu, Yasuyoshi Kimura, Yasufumi Gon, Fumiko Murata, Megumi Maeda, Kosuke Kiyohara, Tetsuhisa Kitamura, Haruhisa Fukuda

International Journal of Geriatric Psychiatry · 2025-01 · 40 (1)

DOI: 10.1002/gps.70036 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objectives Anticholinergic drugs can cause cognitive impairment. The risk of dementia associated with anticholinergics compared to beta‐3 agonists (mirabegron and vibegron) has not been extensively investigated in the super‐aging society of Japan. This study evaluated the association between the dementia risk and anticholinergics compared to beta‐3 agonists in older adults with overactive bladder in Japan. Methods This study had 1,493,202 participants from the Longevity Improvement & Fair Evidence Study, which includes claim data in Japan from 2014 to 2022. The participants included 13,448 anticholinergic drug users and 24,669 beta‐3 agonist users diagnosed with overactive bladder and aged ≥ 65 years. The Cox proportional hazards regression model was used to calculate hazard ratios and 95% confidence intervals being adjusted for confounding variables to evaluate the impact of anticholinergic drugs compared to beta‐3 agonists prescribed at index date to patients with overactive bladder. Results Among the beta‐3 agonist and anticholinergic drug users, the mean (standard deviation) age was 78.9 (6.7) and 78.8 (7.0) years, and the percentage of men was 47.2% and 39.7%, respectively. In the beta‐3 agonist group, 2130 participants were newly diagnosed with dementia during the 51,605 person‐years of follow‐up from the index date, whereas in the anticholinergic drug group, 1826 participants were diagnosed during the 34,929 person‐years of follow‐up. In the Cox proportional hazard regression model, there was an increased risk of dementia in the anticholinergic drug group compared to the beta‐3 agonist group (adjusted hazard ratio [aHR] = 1.22; 95% confidence interval [CI], 1.15–1.30). The increased risk remained identical when Inverse Probability Weighting (IPW) model was used for the analysis (aHR = 1.19; 95% CI, 1.11–1.28). Conclusions Compared to beta‐3 agonists, anticholinergic drugs are associated with an increased risk of dementia in older adults with overactive bladder, in Japan. These findings suggest that beta‐3 agonists may have a lower risk of dementia than anticholinergics and have potential to be a good alternative opinion for older people with OAB, which warrants further study.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →